All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

AML Hub

AML Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

MPN Hub

MPN Hub

Multiple Myeloma

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact
SubtypesTherapeuticsCongressesTrialsExpert OpinionsDRUG UPDATES
2020-06-24T07:33:58.000Z

What was new in aggressive NHL at #ASCO20 and EHA 2020?

By Claire Baker
Featured
Ulrich Jäger
Jun 24, 2020
Share:

Bookmark this article

The Lymphoma Hub was delighted to host an interview with Ulrich Jäger, Medical University of Vienna, Vienna, AT. We asked, What was new in aggressive non-Hodgkin lymphoma at this year's American Society of Clinical Oncology (ASCO) and European Hematology Association (EHA) virtual meetings?

This interview outlines three main fields of development:

  1. Chimeric antigen receptor (CAR) T-cell therapies
  2. CD19/CD22 bicistronic CARs
  3. Bispecific antibodies

What was new in aggressive NHL at ASCO and EHA 2020?

More about...
CAR therapyEHA 2020T-cell engagers

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Related articles

Add bookmark

What are the key updates from ESH: 2nd How I manage: CAR T therapies and bispecific antibodies?

During the European Society of Hematology (ESH) 2nd How I manage: CAR T therapies and bispecific antibodies for my patients 2023 Congress, the Lymphoma...

Nov 10, 2023
Add bookmark

What are the key updates from ESH: 2nd How I manage: CAR T therapies and bispecific antibodies?

During the European Society of Hematology (ESH) 2nd How I manage: CAR T therapies and bispecific...

Nov 10, 2023
Add bookmark

Practice-changing abstracts in indolent lymphoma at EHA 2020

Interview with Martin Dreyling outlining the practice-changing abstracts in indolent lymphoma from EHA 2020.

Jul 21, 2020
Add bookmark

Practice-changing abstracts in indolent lymphoma at EHA 2020

Interview with Martin Dreyling outlining the practice-changing abstracts in indolent lymphoma from EHA 2020.

Jul 21, 2020

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox